A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.

Trial Details

NCT ID
NCT07011004
Phase
PHASE1
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Cytokine Induced Memory-Like Natural Killer Cells
  • Atezolizumb
  • CIML-NK cell therapy
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Disease specific inclusion criteria:
  • Subjects must have histologically confirmed acute myeloid leukemia that meets any of the following criteria:
  • Refractory to at least two attempts at prior induction therapy. An attempt is defined as either a single cycle of combination chemotherapy such as …
  • Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →